Dave Lennon, president of AveXis, a Novartis company, says alternative payment models offer a way to ease some of the existing pricing pressure because “we find a mechanism to give value back.”
Lennon made the comments during Phacilitate this month in Miami, FierceHealthcare reports.
” … I think we do have an opportunity to reset the paradigm under which we’re discussing what we should be charging for medicine, justifying that, and then really staying behind that based on outcomes.”
Alternative models could also help alleviate concerns by payers that feel they’ve been “burned too many times” by drug companies whose target populations become higher than expected.
“Payers just don’t trust we’re being specific about who we’re going to go after and we’re being transparent about what we really want from them,” he said.